Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsMEX:HALO 89 Piotroski F-Score is 5 as of Aug. 20, 2026, which is at its 10-year median of 5.00. GuruFocus rates MEX:HALO with a GF Score™ of 89/100 and a GF Value™ of MXN1,579.10 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,335 Biotechnology companies, Halozyme Therapeutics ranks better than 84.94% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Halozyme Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Halozyme Therapeutics's Piotroski F-Score or its related term are showing as below:
MEX:HALO'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 9
Current: 5
During the past 13 years, the highest Piotroski F-Score of Halozyme Therapeutics was 9. The lowest was 2. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Halozyme Therapeutics Piotroski F-Score Related Terms
Halozyme Therapeutics Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HALO vs NUVL, KRYS, IONS: Piotroski F-Score Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was 3214.362 + -2549.445 + 2705.789 + 4011.752 = MXN7,382 Mil. Cash Flow from Operations was 3276.219 + 3943.77 + 3247.293 + 4203.307 = MXN14,671 Mil. Revenue was 6498.69 + 8134.381 + 6793.062 + 8392.952 = MXN29,819 Mil. Gross Profit was 5485.319 + 6716.072 + 5364.187 + 7011.497 = MXN24,577 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(38673.275 + 40746.724 + 45470.208 + 48196.34 + 44973.192) / 5 = MXN43611.9478 Mil. Total Assets at the begining of this year (Jun25) was MXN38,673 Mil. Long-Term Debt & Capital Lease Obligation was MXN33,811 Mil. Total Current Assets was MXN16,280 Mil. Total Current Liabilities was MXN6,010 Mil.
Net Income was 2697.788 + 2857.481 + 2416.011 + 3109.831 = MXN11,081 Mil.
Revenue was 5711.841 + 6215.165 + 5418.579 + 6133.028 = MXN23,479 Mil. Gross Profit was 4738.628 + 5338.079 + 4428.341 + 5260.125 = MXN19,765 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(36080.582 + 41704.646 + 43035.257 + 44937.091 + 38673.275) / 5 = MXN40886.1702 Mil. Total Assets at the begining of last year (Jun24) was MXN36,081 Mil. Long-Term Debt & Capital Lease Obligation was MXN28,415 Mil. Total Current Assets was MXN21,139 Mil. Total Current Liabilities was MXN2,528 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Halozyme Therapeutics's current Net Income (TTM) was 7,382.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Halozyme Therapeutics's current Cash Flow from Operations (TTM) was 14,671.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Halozyme Therapeutics's return on assets of this year was 0.19089301. Halozyme Therapeutics's return on assets of last year was 0.30712118.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Halozyme Therapeutics's gearing of this year was 0.77526113. Halozyme Therapeutics's gearing of last year was 0.69498184.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Halozyme Therapeutics's current ratio of this year was 2.70882226. Halozyme Therapeutics's current ratio of last year was 8.36056071.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Halozyme Therapeutics's number of shares in issue this year was 121.215. Halozyme Therapeutics's number of shares in issue last year was 124.158.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Halozyme Therapeutics's gross margin of this year was 0.82420621. Halozyme Therapeutics's gross margin of last year was 0.84183734.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Halozyme Therapeutics's asset turnover of this year was 0.77105146. Halozyme Therapeutics's asset turnover of last year was 0.65072711.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
0
+
0
+
1
+
0
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Halozyme Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Halozyme Therapeutics (MEX:HALO) has a Piotroski F-Score of 5 as of Aug. 20, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Halozyme Therapeutics and its competitors. This is near median its historical median of 5.00. Over the past decade, Halozyme Therapeutics' Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Halozyme Therapeutics ranks #201 out of 1335 companies in the Biotechnology industry, placing it in the top 15.1%.
Is Halozyme Therapeutics' Piotroski F-Score too high?
Halozyme Therapeutics' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Halozyme Therapeutics' value of 5 is 66.7% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #201 out of 1335 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Halozyme Therapeutics has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Piotroski F-Score compare to NUVL and KRYS?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #201 out of 1335 companies for Piotroski F-Score. This places Halozyme Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Halozyme Therapeutics' value of 5 is 66.7% above this benchmark. Historically, Halozyme Therapeutics' own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,335 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MEX:HALO) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,579.10, compared to a current price of MXN1,740.00 — trading 10.2% above its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 66.7% above the Biotechnology industry median of 3.00. Halozyme Therapeutics' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Halozyme Therapeutics (MEX:HALO), the current Piotroski F-Score is 5 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (MEX:HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued.
The current stock price of MXN1,740.00 is trading 10.2% above its estimated GF Value™ of MXN1,579.10.
GuruFocus considers Halozyme Therapeutics to be Fairly Valued.
Key valuation signals for MEX:HALO:
Piotroski F-Score: 5 (near median its 10-year median of 5.00)
GF Value™: MXN1,579.10 vs. price of MXN1,740.00 (10.2% above fair value)
Industry Position: 66.7% above the Biotechnology median (#201 of 1335)
No single metric tells the full story. See the MEX:HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
89GF Score
Get the complete analysis for MEX:HALO
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HALO has been successfully added to your 
